Watanabe A
Department of Medicine, Tohoku University.
Nihon Rinsho. 1992 May;50(5):1060-5.
The incidence of gentamicin-resistant MRSA (GMr-MRSA) has been gradually increasing since early 1980's in Japan. The GMr-MRSA mainly belongs to Group-I phage type and to Group-IV coagulase type. It is rather difficult to induce methicillin-resistance in the GMr-MRSA in the presence of beta-lactam antibiotics. Since late 1980's tobramycin-resistant MRSA (TOBr-MRSA) has been increasing rapidly in place of GMr-MRSA. The TOBr-MRSA mostly belongs to Group III phage type and Group II coagulase type. It rapidly acquires resistance to methicillin and becomes highly resistant to many other related antibiotics as evidenced by statistics in 1980's in Japan. A combination chemotherapy with imipenem/cilastatin and 1st or 2nd generation cephem, or minocycline plus cephem is considered to be effective for MRSA infections. However, a combination chemotherapy with arbekacin (ABK), or vancomycin (VCM) plus beta-lactam antibiotic is recommended especially for the treatment of respiratory tract infections.
自20世纪80年代初以来,耐庆大霉素的耐甲氧西林金黄色葡萄球菌(GMr-MRSA)在日本的发病率一直在逐渐上升。GMr-MRSA主要属于I组噬菌体类型和IV组凝固酶类型。在β-内酰胺类抗生素存在的情况下,在GMr-MRSA中诱导耐甲氧西林性相当困难。自20世纪80年代末以来,耐妥布霉素的耐甲氧西林金黄色葡萄球菌(TOBr-MRSA)已迅速增加,取代了GMr-MRSA。TOBr-MRSA大多属于III组噬菌体类型和II组凝固酶类型。它迅速获得对甲氧西林的耐药性,并对许多其他相关抗生素产生高度耐药性,20世纪80年代日本的统计数据证明了这一点。亚胺培南/西司他丁与第一代或第二代头孢菌素联合化疗,或米诺环素加头孢菌素被认为对耐甲氧西林金黄色葡萄球菌感染有效。然而,特别是对于呼吸道感染的治疗,推荐阿贝卡星(ABK)或万古霉素(VCM)加β-内酰胺类抗生素联合化疗。